Navigation Links
Celsion Completes Enrollment in Phase I Liver Cancer Study

COLUMBIA, Md.--(BUSINESS WIRE)--May 30, 2007 - CELSION CORPORATION (AMEX:CLN) today announced the completion of its Phase I dose escalation study, using ThermoDox(R), to treat non-resectable liver cancer. The study which was conducted under a Cooperative Research and Development Agreement (CRADA) was performed at the National Cancer Institute (NCI) of the National Institutes of Health, under the leadership of Dr. Steven K. Libutti, Senior Investigator, Head, Tumor Angiogenesis Section, Surgery Branch, Center for Cancer Research, NCI and Dr. Bradford J. Wood, Chief, Interventional Radiology Research at the National Institutes of Health Clinical Center and at Queen Mary Hospital in Hong Kong under the leadership of Dr. Ronnie T. P. Poon, MD, Professor of Surgery, Faculty of Medicine at Queen Mary Hospital, University of Hong Kong.

In the study, a total of 24 primary and metastatic liver cancer patients, with up to 4 lesions ranging from 3 to 7 centimeters, were treated with ThermoDox in combination with radiofrequency ablation at doses ranging from 20 to 60 mg/m2. Enrollment in the study has been completed, and clinical data is currently being assembled for analysis and eventual submission for the FDA. While the Phase I study was designed to determine the maximum safe dose and safety profile of ThermoDox, additional analyses will be undertaken to evaluate any clinical effects achieved during the study.

Michael H. Tardugno, Celsion's President and Chief Executive Officer, commented "Completion of the liver cancer Phase I dosing escalation study represents another milestone in our ThermoDox development program and is consistent with our timelines to initiate our Phase III registrational study for Primary Liver Cancer later this year."

Celsion has licensed the global rights to the temperature-sensitive liposome technology from Duke University where ThermoDox is also being used in a Phase I clinical stu
'"/>




Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Celsion Completes Enrollment Phase Liver Cancer Study
(Date:10/1/2014)... October 1, 2014 Sophia Genetics, ... Sequencing (NGS) data analysis, today launches a unique CFTR ... analysis in a single NGS experiment. The CE-IVD marked ... of variants in a single NGS experiment with clinical ... not been possible to simultaneously analyse all relevant CFTR ...
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... MacMillan , Hologic,s President and Chief Executive Officer, will ... on October 1, the first day of Breast Cancer ... the Company,s campaign focused on the important benefits of ... by the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... 2014 STUDY OBJECTIVES The objective ... provide an overview of the current and future ... The key objective is to present a comprehensive ... an important tool in the treatment of various ... strategies within the protein therapeutics market, which includes ...
Breaking Medicine Technology:Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... Week announced today that it has entered into an ... the #1 source for Orthopedic Industry News, to more ... most prominent investors and decision makers around the world. ... central bankers, finance ministers and others.  By adding Orthopedics ...
... ADDISON, Texas, June 14, 2011 ULURU Inc. ... on the development of a portfolio of wound management and ... convertible debt financing with Kerry P. Gray, the Company,s Chairman, ... the funds for general corporate purposes. The convertible ...
Cached Medicine Technology:Orthopedics This Week Now on Bloomberg 2ULURU Inc. Raises $140,000 in Convertible Debt Offering 2
(Date:10/2/2014)... Dennis Thompson HealthDay ... Forty-two states and the District of Columbia now have a ... respiratory illness that has been infecting children since the ... with the virus have died in recent weeks, but it,s ... played in those deaths, officials said. Health officials are ...
(Date:10/1/2014)... today in the Journal of the American Medical ... years with moderate or severe chronic knee pain, acupuncture ... University of Melbourne randomly assigned 282 patients (50 years ... or sham or pretend laser treatment. , Treatments ... blinded to laser and sham (inactive) laser acupuncture. , ...
(Date:10/1/2014)... that encourages people to keep their "eyes on the ... exercise. When walking, staying focused on a specific target ... and help people walk there faster, psychology researchers have ... while looking around the environment naturally, offers a new ... are less interested in exercise if physical activity seems ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new ... insurance prices for smokers. , Smoking will always have ... quotes is the best method to find affordable coverage. ... who need coverage. , Whole life insurance premiums ... policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... October 01, 2014 Join the more than ... Disorder Treatment Center’s first ever charity golf tournament to benefit ... with eating disorders who cannot afford treatment. The tournament will ... in Eureka, Mo. , The day-long event starts with ... reception and award dinner will begin at 5 p.m. and ...
Breaking Medicine News(10 mins):Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... at PA Velodrome BREINIGSVILLE, Pa., April 26 In just ... Paradysz bested the 24-hour track record at the Valley ... a new record of 416.09 miles (669.63 kilometers) biked in ... was set in 1980. Paradysz undertook this daunting physical challenge ...
... A team of scientists at The Campbell Family ... Hospital and international collaborators have discovered how to trigger ... included in new clinical trials that use a patient,s ... online today in Nature Medicine (DOI: 10.1038/nm.1953), ...
... found they also reduced chances of erectile dysfunction , , ... statins help prevent prostate cancer and reduce the risk ... there seems to be mounting evidence that there may ... treatment or prostate cancer prevention," said Dr. Lionel L. ...
... Inc. and the California Family Health Council have released a statewide ... ... (PRWEB) April 26, 2009 -- ISIS, Inc., has partnered with the ... Health (CDPH), STD Control Branch, to launch a statewide text messaging ...
... statins may reduce inflammation in prostate tumors, possibly hindering ... in the Duke Prostate Center. , "Previous studies have ... lower incidence of advanced prostate cancer, but the mechanisms ... largely unknown," said Lionel Baez, M.D., a researcher in ...
... red under blue light allows physicians to more easily ... which these cancers come back, says a Mayo Clinic ... international clinical trial. , VIDEO ALERT: Additional audio and ... Lance Mynderse describing the research, are available on the ...
Cached Medicine News:Health News:Father Breaks Cycling Record To Honor Daughter's Fight Against Lupus 2Health News:Scientists discover how to improve immune response to cancer at Princess Margaret Hospital 2Health News:Statins Guard Against Prostate Cancer 2Health News:Statins Guard Against Prostate Cancer 3Health News:Statins Guard Against Prostate Cancer 4Health News:HookUp: Sexual Health Info Text Messaging Service for California Youth Launches 2Health News:Statins may exert influence on prostate cancer growth by reducing inflammation 2Health News:Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence 2Health News:Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence 3
Dust covers for a variety of Zeiss microscopes...
These objectives have more contrast than the DLL objectives for enhanced contrast with tissue culture specimens. These objectives are designed for use on inverted microscopes and therefore their mark...
... Axiovert 40 inverted ... you have ever expected from a microscope in ... outstanding quality, and functionality. Axiovert 40 has been ... safe as possible thus increasing the efficiency ...
... TE2000E is an advanced inverted microscope for ... imaging ports, high resolution CFI60 optics, and ... imaging workstation. In addition, its super-nanoprecision z-axis ... is perfect for precise imaging in 3D. ...
Medicine Products: